Quality Assurance in Immunohistochemistry: Results of an Interlaboratory Trial Involving 172 Pathologists

The practicability of quality assurance in immunohistochemistry and its integration into the diagnostic process were both tested in this Germany-wide interlaboratory trial. One hundred seventy-two pathologists received one hematoxylin and eosin and five unstained slides from five cases; all cases were selected by a panel because immunohistochemistry was required for their final diagnosis. Participants rendered a morphologic diagnosis and then substantiated it immunohistochemically. Stained slides and evaluation sheets were reviewed by the panel, and the diagnostic process was analyzed in individual steps: morphologic diagnosis, selection of antibodies, staining quality, interpretation of stained slides, conclusions, and final diagnosis. Diagnosis-independent immunohistochemical performance was tested using a multisample tissue block (30 samples) that was stained and evaluated for six common antigens. For individual cases, corresponding to their difficulty, 21–89% of the final diagnoses (altogether 57% from 828 diagnoses) were correct. In a statistical analysis, the tentative diagnosis, the interpretation of stains and conclusions drawn from immunohistochemistry, were independent factors in reaching the diagnosis. Sensitivity to detect estrogen receptors on the multisample tissue block was only 48%. However, 24% of the stains were interpreted as falsely negative. The low staining sensitivity was not correlated to the number of correct diagnoses. The major problem of applying immunohistochemistry in surgical pathology appears to be its integration into the diagnostic process and not the staining quality. Both future quality control projects and training will have to regard these integrative requirements. Multisample tissue blocks provide a promising tool to standardize quantitative immunohistochemical parameters, such as receptor or proliferation scores.

[1]  C. Taylor Report from the Biological Stain Commission: FDA issues final rule for classification/reclassification of immunochemistry (IHC) reagents and kits. , 1998, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[2]  Kraemer Bb Quality assurance activities of the College of American Pathologists. , 1989 .

[3]  G. J. Reynolds External quality assurance and assessment in immunocytochemistry , 1989, Histopathology.

[4]  S. Mills,et al.  Consensual interpretive guidelines for diagnostic immunohistochemistry. , 2001, The American journal of surgical pathology.

[5]  E. Campo,et al.  Expression of cytokeratins in squamous cell carcinomas of the larynx: immunohistochemical analysis and correlation with prognostic factors. , 1993, Pathology, research and practice.

[6]  T. Seidal,et al.  Interpretation and Quantification of Immunostains , 2001, The American journal of surgical pathology.

[7]  R. Rickert,et al.  Intralaboratory quality assurance of immunohistochemical procedures. Recommended practices for daily application. , 1989, Archives of pathology & laboratory medicine.

[8]  L. Bobrow,et al.  Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. , 2001, American journal of clinical pathology.

[9]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[10]  C. Taylor Quality assurance and standardization in immunohistochemistry. A proposal for the annual meeting of the Biological Stain Commission, June, 1991. , 1992, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[11]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  W. Remmele,et al.  Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer , 2004, Virchows Archiv A.

[13]  C. Compton,et al.  College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. , 2000, Archives of pathology & laboratory medicine.

[14]  B. Jasani,et al.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries , 2000, Journal of clinical pathology.

[15]  C. Taylor FDA issues final rule for classification and reclassification of immunochemistry reagents and kits. , 1999, American journal of clinical pathology.

[16]  S. Martino,et al.  Estrogen receptor (ER) and progesterone receptor (PgR), by ligand‐binding assay compared with ER, PgR and pS2, by immuno‐histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study , 2000, International journal of cancer.

[17]  P. Swanson Diagnostic immunohistochemistry. A practical primer for the benighted bureaucrat. , 1993, American Journal of Clinical Pathology.

[18]  R. Cote,et al.  Antigen Retrieval Immunohistochemistry: Past, Present, and Future , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  C. Taylor,et al.  Intracellular immunoglobulins , 1974, Journal of clinical pathology.

[20]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[21]  J. Papadimitriou,et al.  The total test approach to standardization of immunohistochemistry. , 2009, Archives of pathology & laboratory medicine.

[22]  C. Compton,et al.  College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants. , 2000, Archives of pathology & laboratory medicine.

[23]  C. Taylor,et al.  An exaltation of experts: concerted efforts in the standardization of immunohistochemistry. , 1994, Human pathology.

[24]  I. Lauder,et al.  Comparative quality assessment in immunocytochemistry: pilot study of CD15 staining in paraffin wax embedded tissue in Hodgkin's disease. , 1989, Journal of clinical pathology.

[25]  P. Swanson Labels, disclaimers, and rules (oh, my!). Analyte-specific reagents and practice of immunohistochemistry. , 1999, American journal of clinical pathology.

[26]  H. Höfler,et al.  [Immunohistochemistry Circle Trial of the University Institute of Pathology in Germany]. , 1997, Der Pathologe.

[27]  R. Cote,et al.  Immunohistochemical markers of prognostic value in surgical pathology. , 1997, Histology and histopathology.